Opens in a new tab or window Once-daily roflumilast cream at 0.15% improved symptoms of atopic ... a range of treatments, unmet needs persist. First, crisaborole and the topical calcineurin ...
A 0.15% once-daily roflumilast cream improved symptoms of atopic dermatitis (AD) across multiple endpoints, according to ...
In this Q&A, Marty Becker, DVM, Elite FFCP-V and Paul Bloom, DVM, DACVD, DABVP (Canine and Feline), Elite FFCP-III share ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.
Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...
Silverberg, J.I., Rosmarin, D., Chovatiya, R. et al. The regulatory T cell-selective interleukin-2 receptoragonist rezpegaldesleukin in the treatment of inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback